Dabigatran antithrombotics
systematic review meta-analysis network meta-analysis
 

Pradax - Pradaxa      

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultMajor bleedingAll cause death

acute coronary syndrome  

REDEEM, 2009    NCTdabigatranplaceboLow risk of bias negative

atrial fibrillation  

RE-LY 110mg (2nd prevention subgroup) , 2010   dabigatran 100mgwarfarinExploratory suggesting
RE-LY 150mg (2nd prevention subgroup)   dabigatran 150mgwarfarinExploratory suggesting
phase 2 dabigatran    NCTdabigatranwarfarin standard doseExploratory -
RE-LY (110mg), 2009      NCTdabigatran 110mgwarfarin standard doseRisk of bias suggesting-20%-9%
PETRO (150mg), 2007     dabigatran 150mgwarfarin standard doseExploratory -
RE-LY (150mg), 2009      NCTdabigatran 150mgwarfarin standard doseRisk of bias suggesting -7%-12%

post acute coronary syndromes  

REDEEM, 2009    NCTdabigatranplaceboLow risk of bias negative

post myocardial infarction  

REDEEM, 2009    NCTdabigatranplaceboLow risk of bias negative

thrombosis prevention  

RE-NOVATE (150mg), 2007      NCTdabigatran 150mgenoxaparinhip surgeryLow risk of bias negative -17%
RE-NOVATE (220mg), 2007      NCTdabigatran 220mgenoxaparinhip surgeryLow risk of bias negative29%∞%
RE-NOVATE 2    NCTdabigatran 220mgenoxaparinhip surgeryLow risk of bias negative
RE-MODEL (150mg), 2007     dabigatran 150mgenoxaparin (europe regimen)knee surgeryLow risk of bias negative-1%-2%
RE-MODEL (220mg), 2007   dabigatran 220mgenoxaparin (europe regimen)knee surgeryLow risk of bias negative14%1%
RE-MOBILIZE (150mg), 2008     dabigatran 150mgenoxaparin (US regimen)knee surgeryLow risk of bias negative -58%∞%
RE-MOBILIZE (220mg), 2008     dabigatran 220mgenoxaparin (US regimen)knee surgeryLow risk of bias negative -58%

venous thrombosis  

RE-MEDY, 2011      NCTdabigatranwarfarinLow risk of bias suggesting-48%-11%
RE-SONATE, 2011    NCTdabigatrandiscontinuationLow risk of bias suggesting∞%-100%
RE-COVER, 2009      NCTheparin/dabigatranheparin/VKA heparin - DOAC Low risk of bias suggesting-17%-1%
RE-COVER II, 2011    NCTheparin/dabigatranheparin/VKA heparin - DOAC Low risk of bias suggesting-31%



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons